Preliminary report of tolvaptan treatment in Japanese patients with heart failure.
暂无分享,去创建一个
R. Nagai | Y. Uchino | Y. Hirata | H. Iwata | K. Kinugawa | Go Nishimura | Norihiko Takeda | T. Shiga | H. Semba | E. Hasumi | Hajime Abe | Tsukasa Inajima | Yumiko Terada | A. Yonenaga
[1] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[2] M. Kawana,et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. , 2010, American heart journal.
[3] H. Shimokawa,et al. Chronic heart failure in Japan: Implications of the CHART studies , 2008, Vascular health and risk management.
[4] G. Fonarow,et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. , 2000, American heart journal.
[5] Christopher M O'Connor,et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. , 2004, JAMA.
[6] M. Domanski,et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.
[7] M. Hori,et al. An Open-Label Study of Tolvaptan in the Heart Failure Patients With Volume Overload , 2010 .
[8] K. Nakao,et al. Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes , 2003, Circulation.
[9] M. Drazner,et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.
[10] Y. Kagaya,et al. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. , 2004, Circulation journal : official journal of the Japanese Circulation Society.
[11] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[12] M. Isobe,et al. The Inhibitor of NF-κB Kinase Plays a Pivotal Role in the Development of Autoimmune Myocarditis in Rats , 2010 .
[13] T Yamashita,et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.
[14] G. Fonarow,et al. Relation of loop diuretic dose to mortality in advanced heart failure. , 2006, The American journal of cardiology.
[15] N Freemantle,et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.
[16] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[17] E. Espiner,et al. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. , 1980, Clinical science.